Nov 8, 2018 • 4:10pm EST

Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results

-- Announced Agreement with Cedars-Sinai Medical Center to Co-fund a Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C -- -- Strengthened Balance Sheet in Support of Microbiome-Focused Clinical Development Programs -- -- Conference Call Today, November 8, 2018, at 4:30 p.m. (EST) -- ROCKVILLE, Md., Nov. 8, 2018 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today provided an operational update and reported financial results for the three and nine months ended Septem...